Answers are grounded in this paper and cite their sources.
β-thalassemia and sickle -cell disease are both serious inherited blood disorders caused by hemoglobin subunit beta (HBB) gene mutations. While conventional treatments such as blood transfusion combined with iron chelation therapy and allogeneic stem cell transplantation, they often require long-term medical support and many carry risks, especially in younger patients. Meanwhile, recent advances in CRISPR-Cas9 gene editing have made it possible to explore more precise genetic therapies, although the clinical use of this technology is still limited by safety concerns and the need for more reliable delivery methods. This study aims to investigate the clinical application potential of CRISPR-series editing technologies, with HbF reactivation pathways as the central focus. Research findings indicate that the BCL11A enhancer target within the CRISPR-Cas9 system demonstrates greater clinical translation maturity; however, when using base editing to target the HBG promoter, this approach outperforms CRISPR-Cas9-mediated BCL11A targeting across multiple key aspects, including HbF enhancer editing strategies and hematopoietic reconstitution. We also found that SCD patients struggle to mobilize their hematopoietic stem cell. Furthermore, this paper systematically summarizes the complete workflow of this gene editing therapies and defines the current limitations and technical gaps in clinical translation. The clinical shortcomings and mechanistic controversies synthesized herein may serve as a literature basis and provide research directions for the future development of low-toxicity conditioning regimens, novel hematopoietic mobilization agents, and precise fetal hemoglobin efficacy assessment systems.
No takes yet. Share an insight, caveat, or question.
Leiruolin Zhu (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: